Vorolanib is a chemically defined substance encountered in pharmaceutical manufacturing whose health-based exposure limit derivation requires integration of pharmacological, toxicokinetic, and general toxicological data to identify the most relevant point of departure. The quality and completeness of the toxicological database for Vorolanib directly influences the magnitude of uncertainty factors applied and the confidence in the resulting PDE value. Periodic review of new published data and post-market clinical safety signals ensures that the OEL for Vorolanib remains protective as scientific knowledge develops.
Study duration uncertainty factor F3 in PDE derivation for Vorolanib compensates for the data gap between the duration of available toxicology studies and the chronic lifetime pharmaceutical exposure scenario. F3 equals 1 when a ≥12-month rodent study or 9-month non-rodent study forms the basis; F3 is set at 2 for 6-month studies, 5 for 13-week sub-chronic studies, and up to
